Search

Your search keyword '"Liang, Yu-Jing"' showing total 213 results

Search Constraints

Start Over You searched for: Author "Liang, Yu-Jing" Remove constraint Author: "Liang, Yu-Jing"
213 results on '"Liang, Yu-Jing"'

Search Results

2. Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial

3. Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial

4. A phase II randomised controlled trial of adjuvant tumour-infiltrating lymphocytes for pretreatment Epstein-Barr virus DNA-selected high-risk nasopharyngeal carcinoma patients

12. Development and validation of a normal tissue complication probability model for acquired nasal cavity stenosis and atresia after radical radiotherapy for nasopharyngeal carcinoma

13. Low value of whole-body dual-modality [18f]fluorodeoxyglucose positron emission tomography/computed tomography in primary staging of stage I–II nasopharyngeal carcinoma: a nest case-control study

15. Genetic Associations of Primary Angle-Closure Disease

24. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II–IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial

25. Concurrent chemoradiotherapy followed by adjuvant cisplatin–gemcitabine versus cisplatin–fluorouracil chemotherapy for N2–3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial

27. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein–Barr virus DNA level and tumor response to palliative chemotherapy

30. Concurrent Chemoradiotherapy Followed by Adjuvant Cisplatin-Gemcitabine Versus Cisplatin-5-Fluorouracil Chemotherapy for N2-3 Nasopharyngeal Carcinoma: A Multicentre, Open-Label, Randomised, Controlled, Phase 3 Trial

33. Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial

36. Effect of Concurrent Chemoradiotherapy With Nedaplatin vs Cisplatin on the Long-term Outcomes of Survival and Toxic Effects Among Patients With Stage II to IVB Nasopharyngeal Carcinoma

37. The prognostic role of plasma Epstein–Barr virus DNA levels in the middle of intensity-modulated radiotherapy to guide cisplatin dose recommendation in concurrent chemoradiation therapy in patients with locally advanced nasopharyngeal carcinoma: A large cohort study

39. Identifying distinct risks of treatment failure in nasopharyngeal carcinoma: Study based on the dynamic changes in peripheral blood lymphocytes, monocytes, N classification, and plasma Epstein‐Barr virus DNA

41. sj-pdf-1-sco-10.1177_2050313X211057704 ��� Supplemental material for Alpha-fetoprotein���producing recurrent nasopharyngeal carcinoma: A case report

43. De-intensified chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma based on plasma EBV DNA: A phase 2 randomized noninferiority trial.

44. Geriatric nutritional risk index as an independent prognostic factor in locally advanced nasopharyngeal carcinoma treated using radical concurrent chemoradiotherapy: a retrospective cohort study

45. Viscosity and surface tension of CaF2–CaO–Al2O3-based slag with varying SiO2and B2O3contents for ESR of rotor steel

46. Nomogram for the prediction of primary distant metastasis of nasopharyngeal carcinoma to guide individualized application of FDG PET/CT

Catalog

Books, media, physical & digital resources